Current understanding of prostate cancer biomarkers-Reference-Cited by-同舟云学术

Current understanding of prostate cancer biomarkers

Published:2024-02-27 Issue:4 Volume:19 Page:148-157
ISSN:1996-1812
Container-title:Cancer Urology
language:
Short-container-title:Onkourologiâ

Author:

Popov S. V.¹^ORCID,Guseynov R. G.²^ORCID,Vasin A. V.³^ORCID,Sivak K. V.⁴^ORCID,Pomeshkin E. V.⁵,Perepelitsa V. V.¹^ORCID,Bunenkov N. S.⁶^ORCID,Lelyavina T. A.⁷

Affiliation:

1. St. Luka’s Clinical Hospital; Saint Petersburg Medical and Social Institute

2. St. Luka’s Clinical Hospital; Saint Petersburg Medical and Social Institute; Saint Petersburg State University

3. Institute of Biomedical Systems and Biotechnologies, Peter the Great Saint Petersburg Polytechnic University

4. St. Luka’s Clinical Hospital; A.A. Smorodintsev Research Institute of Influenza

5. St. Luka’s Clinical Hospital

6. St. Luka’s Clinical Hospital; I.P. Pavlov First Saint Petersburg State Medical University; V.A. Almazov National Medical Research Centre

7. V.A. Almazov National Medical Research Centre

Abstract

Worldwide, prostate cancer has remained one of the most common malignant neoplasms among men and it is accompanied by high mortality rates. Standard methods for diagnosing prostate cancer have limited sensitivity and specificity, unnecessary biopsies are often performed, and the risk of overdiagnosis of the disease and overtreatment of patients is high. The review considers diagnostic and prognostic biological markers of prostate cancer proposed in recent years. Theoretical foundations for the use of new biomarkers are analyzed. The characteristics and practical significance of biomarkers of various groups (immunohistochemical, molecular and genetic, prostate specific antigen-associated, volatile organic metabolites) are presented. The need for further large-scale scientific research in the field of biomarker application in prostate cancer, criteria for their selection and evaluation are described. The introduction of modern diagnostic and prognostic markers into real clinical practice opens up new opportunities for improvement of prostate cancer diagnosis, individual prognosis, and rationalization of treatment strategy.

Publisher

Publishing House ABV Press

Reference70 articles.

1. Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71(3):209–49. DOI: 10.3322/caac.21660

2. Malignant tumors in Russia in 2021 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2022. 252 p. (In Russ.).

3. Dudka I., Thysell E., Lundquist K. et al. Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status. BMC Cancer 2020;20(1):437. DOI: 10.1186/s12885-020-06908-z

4. Prostate cancer. Clinical guidelines. 2021. 124 p. (In Russ.).

5. Lima A.R., Pinto J, Amaro F. et al. Advances and Perspectives in prostate cancer biomarker discovery in the last 5 years through tissue and urine metabolomics. Metabolites 2021;11(3):181. DOI: 10.3390/metabo11030181